基于B7-H3靶点的放射免疫治疗研究进展  

Advances in radioimmunotherapy targeting B7-H3

作　　者：郑梦 王燕[1,2] 傅丰庆[3,4] 缪丽燕[1,2] ZHENG Meng;WANG Yan;FU Feng-qing;MIAO Li-yan(Clinical Pharmacology Research Laboratory,the First Affiliated Hospital of Suzhou University,Suzhou 215006,China;Institute for Interdisciplinary Drug Research and Translational Sciences,College of Pharmaceutical Sciences,Suzhou University,Suzhou 215123,China;Institute of Clinical Immunology,the First Affiliated Hospital of Suzhou University,Suzhou 215006,China;State Key Laboratory of Radiation Medicine and Protection,Suzhou University,Suzhou 215123,China)

机构地区：[1]苏州大学附属第一医院临床药理实验室,苏州215006 [2]苏州大学药学院药物研究与转化交叉研究所,苏州215123 [3]苏州大学附属第一医院临床免疫研究所,苏州215006 [4]苏州大学放射医学与辐射防护国家重点实验室,苏州215123

出　　处：《中国新药杂志》2023年第7期687-694,共8页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助项目(82104318);江苏省重点研发计划(社会发展)专项资助项目(BE2021644)。

摘　　要：近年来,放射免疫治疗(radioimmunotherapy,RIT)因其精准靶向治疗而备受关注。寻找特异性免疫治疗靶点分子用于放射免疫治疗是一种极具临床应用价值的治疗模式。B7-H3(CD276)是B7家族中的一种免疫检查点,因其独特的表达特性和生物学功能,成为RIT药物的一个理想候选分子。本文从B7-H3的表达特点及其生物学功能等方面进行综述,并总结了以B7-H3为靶点的放射免疫治疗最新研究进展。Recently,radioimmunotherapy(RIT)has attracted much attention because of its precision targeted therapy.It is a therapeutic mode with great clinical application value to select an appropriate target molecule for radioimmunotherapy.B7-H3,also known as CD276,is an immune checkpoint molecule belonging to the B7 immunoglobin superfamily,which makes it an ideal candidate for RIT agents due to its unique expression characteristics and biological functions.Herein,we summarize the expression characteristics and biological functions of B7-H3.We also review the latest developments in radioimmunotherapy targeting B7-H3 in the context of cancer therapeutic.

关 键 词：B7-H3 CD276 放射免疫治疗 靶向治疗 肿瘤 

分 类 号：R967[医药卫生—药理学] R979.1[医药卫生—药学]